Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Thyroid Carcinoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Thyroid Carcinoma Disease Pipeline Drugs Assessment

 

Overview:

Thyroid Carcinomais the most common malignant tumor of endocrine system. Most frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have genetic alterations leading to activation of mitogen-activated protein kinase (MAPK) signaling pathway. Thyroid carcinoma manifests as a palpable, painless solitary thyroid nodule. Symptoms associated with thyroid carcinoma are solitary nodules, hard and fixed nodules, neck pain, cough, breathing problem, trouble swallowing, voice changes etc.

Thyroid carcinoma diagnosis includes blood test, fine needle aspiration biopsy, CT scan, Ultrasonography, MRI, Indirect laryngoscopy, PET Scan, Nuclear medicine scan etc. Generally, treatment of thyroid cancers includes chemotherapy, hormone therapy, radiation therapy, surgery, targeted therapy.

 

Segmentation:

By Trial Phase, Thyroid Carcinomapipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Thyroid Carcinomapipeline drugs are segmented as:

  • Eisai Inc.
  • Pfizer
  • Astra Zeneca
  • GlaxoSmithKline
  • Novartis Pharmaceuticals
  • Bayer
  • Sanofi
  • Celldex Therapeutics
  • Genentech, Inc.
  • Others

By Drugs, Thyroid Carcinoma pipeline drugs are segmented as:

  • Pembrolizumab
  • Nivolumab
  • Sorafenib
  • Sulfatinib
  • Anlotinib
  • Nab-paclitaxel
  • Pazopanib Hydrochloride
  • Others

By Types of Thyroid Cancer, Thyroid Carcinoma pipeline drugs are segmented as:

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Hurthle Cell Carcinoma
  • Medullary Thyroid Carcinoma
  • Anaplastic Carcinoma

By Route of Administration, Thyroid Carcinomapipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In March 2017, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.commenced an open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
  • In November 2015, Kolltan Pharmaceuticals, Inc., presented pre-clinical findings which determines that Company’s KTN3379 reverses ErbB3-mediated resistance of BARF and MEK inhibitors in BRAF-mutated thyroid cancer and melanoma. Based on these pre-clinical findings support Kolltan’s ongoing Phase 1b clinical trials in BRAF-mutant tumors and the recently initiated clinical trial in thyroid cancer. In November 2016, Celldex Therapeutics, Inc. acquired Kolltan Pharmaceuticals. Kolltens KTN3379 has changed to CDX_3379.

 

Report Description:

Thyroid CarcinomaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Thyroid Carcinoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Thyroid Carcinoma disease pipeline drugs development. This report studies the dynamics of the Thyroid Carcinoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Thyroid Carcinoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

 

 

  • Eisai Inc.
  • Pfizer
  • Astra Zeneca
  • GlaxoSmithKline
  • Novartis Pharmaceuticals
  • Bayer
  • Sanofi
  • Celldex Therapeutics
  • Genentech, Inc.

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553